Baseline clinical data
| Lactose (n=40) | SMP (n=40) | SMP/GMP/G600 (n=40) | |
|---|---|---|---|
| Age, years, mean (SD) | 57 (16) | 56 (12) | 56 (13) |
| Male, n (%) | 37 (93%) | 36 (90%) | 35 (88%) |
| Caucasian ethnicity, n (%) | 28 (70%) | 28 (70%) | 22 (55%) |
| Age of first episode, years, mean (SD) | 42 (15) | 39 (13) | 43 (13) |
| Number of self-reported flares in preceding 4 months, mean (SD) | 3.9 (2.7) | 4.5 (2.3) | 5.1 (9.6) |
| Allopurinol use, n (%) | 21 (53%) | 22 (55%) | 22 (55%) |
| Colchicine use, n (%) | 12 (30%) | 7 (18%) | 13 (33%) |
| Prednisone use, n (%) | 4 (10%) | 8 (20%) | 4 (10%) |
| NSAID use, n (%) | 11 (28%) | 10 (25%) | 11 (28%) |
| Diuretic use, n (%) | 2 (5%) | 1 (2.5%) | 8 (20%)* |
| Number of gout flares in baseline month, mean (SD) | 1.3 (1.5) | 1.1 (1.4) | 1.8 (2.4) |
| Tender joint count, mean (SD) | 1.1 (1.7) | 0.7 (1.0) | 1.3 (1.7) |
| Swollen joint count, mean (SD) | 0.7 (0.8) | 0.8 (0.9) | 1.1 (2.2) |
| Tophaceous gout, n (%) | 8 (20%) | 17 (43%) | 10 (25%) |
| HAQ-II, mean (SD) | 0.24 (0.44) | 0.32 (0.39) | 0.28 (0.41) |
| Patient global assessment, mean (SD) | 1.8 (1.0) | 2.0 (1.2) | 2.0 (1.2) |
| Pain of self-reported flare in baseline month, mean (SD) | 2.7 (1.6) | 2.6 (1.7) | 3.2 (2.1) |
| Serum urate, mmol/l, mean (SD) | 0.44 (0.11) | 0.41 (0.09) | 0.42 (0.11) |
| Serum creatinine, μmol/l, mean (SD) | 91 (18) | 91 (19) | 93 (20) |
| C reactive protein, mg/l, mean (SD) | 4.7 (6.9) | 3.6 (4.3) | 7.5 (10.1) |
| Fractional excretion of uric acid, %, mean (SD) | 4.7 (1.4) | 4.8 (1.4) | 4.5 (1.8) |
| Number of dairy servings/day, mean (SD) | 2.5 (1.5) | 2.2 (1.7) | 2.7 (1.9) |
| Number of low fat dairy servings/day, mean (SD) | 1.6 (1.5) | 1.2 (1.1) | 1.4 (1.4) |
| Total calcium intake/day, mg, mean (SD) | 819 (471) | 663 (362) | 764 (351) |
GMP, glycomacropeptide; G600, G600 milk fat extract; HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drug; SMP, skim milk powder.
↵* p<0.05 compared with SMP.